Drugs / FLUENZ
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Fluenz | — | 2011-01-27 | europa.eu ↗ |
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02143882 | Sep 2014 → Mar 2017 | — | Public Health England | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06620185 | Apr 2025 → Jul 2026 overdue | influenza | Imperial College London | Recruiting | No outcome recorded |
| — | NCT02642237 | Dec 2015 → Jan 2017 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT01866540 | Oct 2012 → Dec 2025 overdue | tonsillitis | University of Bergen | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLUENZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01866540 ↗ |
| Modality | Vaccine | “live attenuated influenza vaccine” NCT01866540 ↗ |
| Route | Intranasal | “intranasal vaccination” NCT01866540 ↗ |